Compare GXAI & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GXAI | ADXN |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 8.6M |
| IPO Year | 2022 | 2019 |
| Metric | GXAI | ADXN |
|---|---|---|
| Price | $1.22 | $6.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 452.1K | 3.0K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,933,030.00 | N/A |
| Revenue This Year | $271.23 | $86.57 |
| Revenue Next Year | $36.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $1.02 | $5.41 |
| 52 Week High | $2.96 | $12.05 |
| Indicator | GXAI | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 50.40 |
| Support Level | $1.04 | $6.04 |
| Resistance Level | $1.31 | $7.40 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 20.00 | 60.87 |
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.